Evidence map›Paper›PMID 34051628›Full record

ReviewCancer treatment reviews2021

Recent advancements of antiangiogenic combination therapies in ovarian cancer.

Daniel An, Susana Banerjee, Jung-Min Lee

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer treatment reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 2 pooled it
12.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 79 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Kynurenine in IDO1Journal of translational medicine · 2024
    Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Daniel AnWomen's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Susana BanerjeeGynaecology Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK.
Jung-Min LeeWomen's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA. Electronic address: leej6@mail.nih.gov.
National Cancer Institute · USRoyal Marsden NHS Foundation Trust · GB

Funding

Targeting DNA damage repair and related pathways in HRD-womens cancersZIABC011525 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LEE, JUNG-MIN · 2013 to 2025
$14.8M
Intramural NIH HHS Z99 CA999999Intramural NIH HHS ZIA BC011525
6 · The paper itself

Abstract

Ovarian cancer is a deadly malignancy with a growing therapeutic armamentarium, though achieving sustained benefit in the clinic remains largely elusive. Through biomarker and genetic analysis, several pathways of resistance and sensitivity to commonly used therapeutics have been identified, expanding the potential of identifying unique drug combinations and indicating new directions for improving clinical outcomes. Here, we review the mechanisms of angiogenic response and antiangiogenic therapy in ovarian cancer, as well as the interactions it exhibits with the immune and DNA damage response pathways. We discuss results from clinical trials examining the combinations of antiangiogenics, PARP inhibitors, and immune checkpoint inhibitors are also discussed, as well as several ongoing trials.

Indexed as

Molecular Targeted TherapyAngiogenesis InhibitorsAnimalsAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansImmune Checkpoint InhibitorsNeovascularization, PathologicOvarian NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsAngiogenesis InhibitorsImmune Checkpoint InhibitorsPoly(ADP-ribose) Polymerase InhibitorsCombination therapyImmunotherapyOvarian cancerPARP inhibitorVEGF/VEGFR inhibitor

Identifiers

PMID34051628
PMCPMC8217312
OpenAlexW3160208695

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.